SCHEMBL26607349

SCHEMBL26607349

Cc1cc(C(C)(C)C)ccc1-c1cc(=O)c2c(O)cccc2[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC4 P56524 1/20 0.46
▸ HDAC2 Q92769 1/20 0.46
▸ HDAC8 Q9BY41 1/20 0.46
▸ CYP26A1 O43174 1/20 0.37
▸ CYP26B1 Q9NR63 1/20 0.37
▸ ATM Q13315 1/20 0.37
▸ ALDH1A1 P00352 3/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ PLA2G1B P04054 1/20 0.36
▸ NFKB1 P19838 1/20 0.36
▸ CASP3 P42574 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ NFKB2 Q00653 1/20 0.36
▸ RELA Q04206 1/20 0.36
▸ SENP8 Q96LD8 1/20 0.36
▸ SENP7 Q9BQF6 1/20 0.36
▸ SENP6 Q9GZR1 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ ATG4B Q9Y4P1 1/20 0.36
▸ DAO P14920 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26724785 0.85 ALDH1A1 (0.38) CYP26A1CYP26B1ALDH1A1NPC1PLA2G1B
SCHEMBL26606985 0.83 BTK (0.38) CYP26A1CYP26B1PARP1
SCHEMBL26606984 0.83 ALDH1A1 (0.37) HDAC4HDAC2HDAC8CYP26A1CYP26B1
SCHEMBL26607039 0.83 POLH (0.41) ALDH1A1RAB9APARP1HPGDIMPDH2
SCHEMBL26724346 0.82 CSNK1D (0.35) CYP26A1CYP26B1ALDH1A1NPC1PLA2G1B
SCHEMBL26846921 0.79 CTSV (0.54) ALDH1A1NPC1NFKB1RAB9ANFKB2
SCHEMBL26743548 0.78 CYP26A1 (0.35) CYP26A1CYP26B1ALDH1A1NPC1PLA2G1B
SCHEMBL312608 0.77 MGAM (0.40) HPGDIMPDH2IMPDH1MEN1GAA
SCHEMBL26607281 0.75 ALDH1A1 (0.43) CYP26A1CYP26B1ALDH1A1NPC1PLA2G1B
SCHEMBL26724147 0.75 CYP26A1 (0.39) CYP26A1CYP26B1ALDH1A1NPC1PLA2G1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4511114-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN Vertex Pharmaceuticals Incorporated (US) 2025-02-26 — — EP disclosed
US-20230382910-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED 2023-11-30 — — US disclosed
US-20230382910-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED 2023-11-30 — — US disclosed
US-20230382910-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED 2023-11-30 — — US disclosed
WO-2023205778-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 — — WO disclosed
WO-2023205778-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382910-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN TRPV1, SCN3A, KCNN3 HDAC4 1210/4885HDAC2 589/4885HDAC8 1078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback